表紙
市場調査レポート

Actelion Ltd:パイプライン製品の分析

Actelion Ltd - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 207924
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Actelion Ltd:パイプライン製品の分析 Actelion Ltd - Product Pipeline Review - 2016
出版日: 2016年03月30日 ページ情報: 英文 74 Pages
概要

Actelion Ltd.では、数々のアンメットニーズの解消に役立つ革新的治療薬の創薬・開発・販売に従事しています。また、エンドセリン受容体拮抗薬(ERA)の開発を主導してきたという実績があります。同社の主要製品には、Tracleer(ボセンタン、肺動脈高血圧治療薬)やVentavis(iloprost、吸引式のプロスタシクリン合成類似体)、Veletri(注射式エポプロステノール、静脈内プロスタシクリン)、Zavesca(miglustat、低分子量阻害剤)などが含まれています。

当レポートでは、スイスのバイオ医薬品企業、Actelion Ltd(Actelion)における医薬品の研究開発の進捗状況について分析し、同社の製品パイプラインの構造や、治験の全体的な進捗状況、主要なパイプライン製品のプロファイルと開発状況、同社のプロファイルと最新動向などを調査しております。

目次

Actelion Ltd.:現状

  • 企業概要
  • 主要情報
  • 主要データ

研究開発(R&D)の概況

  • 主な治療領域

パイプライン・レビュー

  • 開発段階別のパイプライン製品
  • パイプライン製品:単剤治療薬
  • パイプライン製品:パートナー製品
    • パートナー製品/併用治療モダリティ

パイプライン製品の概要

  • 後期段階のパイプライン製品
    • 登録前製品/併用治療モダリティ
    • 第III相製品/併用治療モダリティ
  • 治験段階のパイプライン製品
    • 第II相製品/併用治療モダリティ
    • 第I相製品/併用治療モダリティ
  • 初期段階のパイプライン製品
    • 治験前製品/併用治療モダリティ
    • 創薬段階の製品/併用治療モダリティ

薬剤のプロファイル

  • マシテンタン
    • 製品の概要
    • 作用機序
    • 研究開発(R&D)の進展
  • ボセンタン
  • cadazolid
  • selexipag
  • ACT-280778
  • ponesimod
  • ACT-246475
  • ACT-281959
  • ACT-389949
  • ACT-434964
  • ACT-462206
  • 喘息・アレルギー症向けCRTH2受容体拮抗薬
  • lucerastat
  • 不眠症向けオレキシン受容体拮抗薬
  • 免疫不全症向けS1P1受容体作動薬
  • 心血管疾患向け小分子
  • 免疫不全症向け小分子
  • マラリア向け小分子
  • 細菌感染症向けDNAギラーゼ・トポイソメラーゼIV阻害用小分子
  • ブドウ球菌感染症向けDNAリガーゼ阻害用小分子
  • 化合物-49c
  • 不眠症向け二重オレキシン受容体拮抗薬
  • がん向け小分子

パイプラインの分析

  • 標的別
  • 投与方法別
  • 分子の種類別
  • 作用機序別

パイプライン製品の最新動向

開発が休止状態の製品

開発が中止された製品

  • 開発が中止された製品のプロファイル
    • アルモレキサント
    • クラゾセンタン
    • palosuran
    • setipiprant

企業のステートメント

事業所および子会社

  • 本社
  • その他の事業所と子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08006CDB

Summary

Global Markets Direct's, 'Actelion Ltd - Product Pipeline Review - 2016', provides an overview of the Actelion Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Actelion Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Actelion Ltd
  • The report provides overview of Actelion Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Actelion Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Actelion Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Actelion Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Actelion Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Actelion Ltd Snapshot
    • Actelion Ltd Overview
    • Key Information
    • Key Facts
  • Actelion Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Actelion Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Actelion Ltd - Pipeline Products Glance
    • Actelion Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Actelion Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Actelion Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Actelion Ltd - Drug Profiles
    • mechlorethamine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selexipag
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cadazolid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • macitentan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponesimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miglustat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clazosentan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cenerimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-082
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACT-451840
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACT-541468
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lucerastat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Neurological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cardiovascular Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-080
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Endothelin A Receptor for Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Ligase for Staphylococcal Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Actelion Ltd - Pipeline Analysis
    • Actelion Ltd - Pipeline Products by Target
    • Actelion Ltd - Pipeline Products by Route of Administration
    • Actelion Ltd - Pipeline Products by Molecule Type
    • Actelion Ltd - Pipeline Products by Mechanism of Action
  • Actelion Ltd - Recent Pipeline Updates
  • Actelion Ltd - Dormant Projects
  • Actelion Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • almorexant
      • selexipag
  • Actelion Ltd - Company Statement
  • Actelion Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Actelion Ltd, Key Information
  • Actelion Ltd, Key Facts
  • Actelion Ltd - Pipeline by Indication, 2016
  • Actelion Ltd - Pipeline by Stage of Development, 2016
  • Actelion Ltd - Monotherapy Products in Pipeline, 2016
  • Actelion Ltd - Partnered Products in Pipeline, 2016
  • Actelion Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Actelion Ltd - Out-Licensed Products in Pipeline, 2016
  • Actelion Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Actelion Ltd - Pre-Registration, 2016
  • Actelion Ltd - Phase III, 2016
  • Actelion Ltd - Phase II, 2016
  • Actelion Ltd - Phase I, 2016
  • Actelion Ltd - Preclinical, 2016
  • Actelion Ltd - Discovery, 2016
  • Actelion Ltd - Pipeline by Target, 2016
  • Actelion Ltd - Pipeline by Route of Administration, 2016
  • Actelion Ltd - Pipeline by Molecule Type, 2016
  • Actelion Ltd - Pipeline Products by Mechanism of Action, 2016
  • Actelion Ltd - Recent Pipeline Updates, 2016
  • Actelion Ltd - Dormant Developmental Projects,2016
  • Actelion Ltd - Discontinued Pipeline Products, 2016
  • Actelion Ltd, Subsidiaries

List of Figures

  • Actelion Ltd - Pipeline by Top 10 Indication, 2016
  • Actelion Ltd - Pipeline by Stage of Development, 2016
  • Actelion Ltd - Monotherapy Products in Pipeline, 2016
  • Actelion Ltd - Partnered Products in Pipeline, 2016
  • Actelion Ltd - Pipeline by Top 10 Target, 2016
  • Actelion Ltd - Pipeline by Route of Administration, 2016
  • Actelion Ltd - Pipeline by Molecule Type, 2016
  • Actelion Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top